MedKoo Cat#: 406293 | Name: MPT0B098
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MPT0B098 is a potent microtubule inhibitor through binding to the colchicine-binding site of tubulin. MPT0B098 is active against the growth of various human cancer cells, including chemoresistant cells with IC50 values ranging from 70 to 150 nmol/L. MPT0B098 arrests cells in the G2–M phase and subsequently induces cell apoptosis. In addition, MPT0B098 effectively suppresses VEGF-induced cell migration and capillary-like tube formation of HUVECs. Distinguished from other microtubule inhibitors, MPT0B098 not only inhibited the expression levels of HIF-1α protein but also destabilized HIF-1α mRNA. The mechanism of causing unstable of HIF-1α mRNA by MPT0B098 is through decreasing RNA-binding protein, HuR, translocation from the nucleus to the cytoplasm. Notably, MPT0B098 effectively suppresses tumor growth and microvessel density of tumor specimens in vivo. Taken together, our results provide a novel mechanism of inhibiting HIF-1α of a microtubule inhibitor MPT0B098. MPT0B098 is a promising anticancer drug candidate with potential for the treatment of human malignancies. (source: Mol Cancer Ther; 2013, 12(7); 1202–12.

Chemical Structure

MPT0B098
MPT0B098
CAS#1254363-89-7

Theoretical Analysis

MedKoo Cat#: 406293

Name: MPT0B098

CAS#: 1254363-89-7

Chemical Formula: C20H18N2O3S

Exact Mass: 366.1038

Molecular Weight: 366.44

Elemental Analysis: C, 65.55; H, 4.95; N, 7.64; O, 13.10; S, 8.75

Price and Availability

Size Price Availability Quantity
10mg USD 550.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
MPT0B098; MPT0B-098; MPT0B 098;
IUPAC/Chemical Name
1-((4-methoxyphenyl)sulfonyl)-7-(pyridin-4-yl)indoline
InChi Key
AGYCYVPAEQVWJT-UHFFFAOYSA-N
InChi Code
InChI=1S/C20H18N2O3S/c1-25-17-5-7-18(8-6-17)26(23,24)22-14-11-16-3-2-4-19(20(16)22)15-9-12-21-13-10-15/h2-10,12-13H,11,14H2,1H3
SMILES Code
O=S(N1CCC2=C1C(C3=CC=NC=C3)=CC=C2)(C4=CC=C(OC)C=C4)=O
Appearance
Solid powder
Purity
>98%
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>5 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
        
Product Data
Biological target:
MPT0B098 is a potent microtubule inhibitor through binding to the colchicine-binding site of tubulin.
In vitro activity:
MPT0B098 significantly inhibited HIF-1α expression, epithelial-to-mesenchymal morphology changes, and migratory ability in the human head and neck squamous cell carcinoma cell line OEC-M1. Furthermore, after MPT0B098 treatment, the expression of two mesenchymal markers, vimentin and N-cadherin, was downregulated under hypoxic conditions. MPT0B098 significantly inhibited transforming growth factor(TGF)-β-induced phosphorylation of receptor-associated Smad2/3 by downregulating TGF-β mRNA and protein expression. Reference: J Biomed Sci. 2018 Mar 28;25(1):28. https://pubmed.ncbi.nlm.nih.gov/29592811/
In vivo activity:
This study recently discovered a novel indoline-sulfonamide compound, 7-aryl-indoline-1-benzene-sulfonamide (MPT0B098), as a potent microtubule inhibitor through binding to the colchicine-binding site of tubulin. Notably, MPT0B098 effectively suppresses tumor growth and microvessel density of mouse tumor specimens in vivo. Reference: Mol Cancer Ther. 2013 Jul;12(7):1202-12. https://pubmed.ncbi.nlm.nih.gov/23619299/

Preparing Stock Solutions

The following data is based on the product molecular weight 366.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Tsai IT, Kuo CC, Liou JP, Chang JY. Novel microtubule inhibitor MPT0B098 inhibits hypoxia-induced epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma. J Biomed Sci. 2018 Mar 28;25(1):28. doi: 10.1186/s12929-018-0432-6. PMID: 29592811; PMCID: PMC5875002. 2. Peng HY, Cheng YC, Hsu YM, Wu GH, Kuo CC, Liou JP, Chang JY, Jin SL, Shiah SG. MPT0B098, a Microtubule Inhibitor, Suppresses JAK2/STAT3 Signaling Pathway through Modulation of SOCS3 Stability in Oral Squamous Cell Carcinoma. PLoS One. 2016 Jul 1;11(7):e0158440. doi: 10.1371/journal.pone.0158440. PMID: 27367272; PMCID: PMC4930189. 3. Cheng YC, Liou JP, Kuo CC, Lai WY, Shih KH, Chang CY, Pan WY, Tseng JT, Chang JY. MPT0B098, a novel microtubule inhibitor that destabilizes the hypoxia-inducible factor-1α mRNA through decreasing nuclear-cytoplasmic translocation of RNA-binding protein HuR. Mol Cancer Ther. 2013 Jul;12(7):1202-12. doi: 10.1158/1535-7163.MCT-12-0778. Epub 2013 Apr 25. Erratum in: Mol Cancer Ther. 2013 Sep;12(9):1919. PMID: 23619299.
In vitro protocol:
1. Tsai IT, Kuo CC, Liou JP, Chang JY. Novel microtubule inhibitor MPT0B098 inhibits hypoxia-induced epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma. J Biomed Sci. 2018 Mar 28;25(1):28. doi: 10.1186/s12929-018-0432-6. PMID: 29592811; PMCID: PMC5875002. 2. Peng HY, Cheng YC, Hsu YM, Wu GH, Kuo CC, Liou JP, Chang JY, Jin SL, Shiah SG. MPT0B098, a Microtubule Inhibitor, Suppresses JAK2/STAT3 Signaling Pathway through Modulation of SOCS3 Stability in Oral Squamous Cell Carcinoma. PLoS One. 2016 Jul 1;11(7):e0158440. doi: 10.1371/journal.pone.0158440. PMID: 27367272; PMCID: PMC4930189.
In vivo protocol:
1. Cheng YC, Liou JP, Kuo CC, Lai WY, Shih KH, Chang CY, Pan WY, Tseng JT, Chang JY. MPT0B098, a novel microtubule inhibitor that destabilizes the hypoxia-inducible factor-1α mRNA through decreasing nuclear-cytoplasmic translocation of RNA-binding protein HuR. Mol Cancer Ther. 2013 Jul;12(7):1202-12. doi: 10.1158/1535-7163.MCT-12-0778. Epub 2013 Apr 25. Erratum in: Mol Cancer Ther. 2013 Sep;12(9):1919. PMID: 23619299.
1: Cheng YC, Liou JP, Kuo CC, Lai WY, Shih KH, Chang CY, Pan WY, Tseng JT, Chang  JY. MPT0B098, a Novel Microtubule Inhibitor That Destabilizes the Hypoxia-Inducible Factor-1α mRNA through Decreasing Nuclear-Cytoplasmic Translocation of RNA-Binding Protein HuR. Mol Cancer Ther. 2013 Jul;12(7):1202-12. doi: 10.1158/1535-7163.MCT-12-0778. Epub 2013 Apr 25. PubMed PMID: 23619299.